Method and compositions for treating diseases targeting CD71
AssigneeApplera Corporation
InventorsBruno Domon, Ian McCaffery, Vaibhav Narayan, Scott Patterson
Life of this patent
Estimating the term…
Abstract
Methods and compositions for diagnosing, detecting and treating a pancreatic disease associated with differential expression of CD71 in comparison to healthy cells. Also provided are antagonists or agonists of CD71, and methods for screening agents that modulate the CD71 level or activity in vivo or in vitro.
Claims18
A method for diagnosing or detecting in a subject a pancreatic cancer, the method comprising:
- determining a test level or test activity of CD71 protein in a pancreatic cell from the subject, and
- determining a control level or control activity in a pancreatic cell from a healthy subject,
- wherein the pancreatic disease is related to abnormal expression or function of CD71 protein, and
- wherein the test level or test activity in the cell from the subject is different from the control level or control activity in a pancreatic cell from a healthy subject is indicative of the presence of the pancreatic cancer.
A method for monitoring treatment of a pancreatic cancer in a subject, wherein the pancreatic cancer is related to abnormal expression or function of CD71 protein, the method comprising:
- determining a first test level or a first test activity of CD71 protein in a pancreatic cell from the subject prior to the treatment,
- determining a second test level or a second test activity of CD71 protein in a pancreatic cell from the subject subsequent to the treatment, and
- determining a control level or control activity in a pancreatic cell from a healthy subject,
- wherein the second test level or second test activity in the cell from the subject approaches the control level or control activity when compared to the first test level or first test activity is indicative of successful treatment.
A pharmaceutical composition comprising an antagonist to CD71 and a pharmaceutically acceptable excipient.
A method of inhibiting cell growth or proliferation comprising contacting cells with CD71 antibody.
A method of inhibiting cell growth or proliferation comprising contacting cells with CD71 RNAi.
A method for screening for an agent that modulates CD71 protein activity, the method comprising:
- (i) contacting a candidate agent with a preparation of CD71 protein, and
- (ii) assaying for a CD71 protein activity, wherein a change in said CD71 protein activity in the presence of said agent relative to a CD71 protein activity in the absence of said agent indicates said agent modulates CD71 protein activity.
A method for screening for an agent that modulates the level of expression of a nucleic acid that codes for a CD71 protein in a cell the naturally expresses the CD71 protein, the method comprises:
- (i) contacting a candidate agent with the cell or a cell-free preparation from the cell wherein CD71 protein is expressed, and
- (ii) assaying for the level of expression of the CD71 protein activity, wherein a change in said level in the presence of said agent relative to a level in the absence of said agent indicates said agent modulates the expression of CD71 protein.
Dependencies are inferred from the claim text.